Catello Somma

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.

We are developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound, nizubaglustat, will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program in the clinic while further expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts.

Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico is initially targeting spinocerebellar ataxia types 3 and 1 and Huntington’s disease. Our VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA. For more information, visit www.vicotx.com

IAB provides an environment that facilitates interactions between interesting start-up projects and its members. Our goal is to identify and nurture top talent entrepreneurs in the Life Sciences sector. We lead equity investments to help ideas and start-ups to reach key objectives. Our value is beyond financing, we do not provide just angel money. We bring mentoring and expertise to great ideas by becoming entrepreneur partners. Our added value is in networking: we connect start-ups with international venture capitals, Life Sciences experts, strategic partners, industry veterans as well as service providers such as law firms, as well as other advisors or service companies. We usually take board seats and work closely with entrepreneurs to maximize the chances of success.

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.

We are developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound, nizubaglustat, will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program in the clinic while further expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts.

Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico is initially targeting spinocerebellar ataxia types 3 and 1 and Huntington’s disease. Our VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA. For more information, visit www.vicotx.com

IAB provides an environment that facilitates interactions between interesting start-up projects and its members. Our goal is to identify and nurture top talent entrepreneurs in the Life Sciences sector. We lead equity investments to help ideas and start-ups to reach key objectives. Our value is beyond financing, we do not provide just angel money. We bring mentoring and expertise to great ideas by becoming entrepreneur partners. Our added value is in networking: we connect start-ups with international venture capitals, Life Sciences experts, strategic partners, industry veterans as well as service providers such as law firms, as well as other advisors or service companies. We usually take board seats and work closely with entrepreneurs to maximize the chances of success.

Investing in life sciences. Investing in life. Seroba is a European life sciences venture capital firm based in Dublin, Paris and Milan, investing its fourth Fund. We focus on value creation through backing cutting-edge biotech and medtech innovation that will transform the treatment of unmet medical needs. Our team has deep industry and operational experience and an extensive global network. We like to work with entrepreneurs who share our passion for success and for investors who share the same goal of improving human health while driving financial returns.